NB Science M3 Mutant Peptide Patent for Myopathy, Obesity, Diabetes
Summary
USPTO granted patent US12605431B2 to NB SCIENCE CO., LTD. on April 21, 2026. The patent covers an M3 mutant peptide composition for treating or preventing myopathy, obesity, or diabetes, listing five claims under CPC classifications including A61K 38/4886 and A61P 3/04. The application (18267252) was filed on December 14, 2021.
“The present invention relates to: an M3 mutant peptide; a composition for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes, comprising same as an active ingredient; a method for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes by using the M3 mutant peptide; and uses of the M3 mutant peptide for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes.”
What changed
USPTO issued patent US12605431B2 to NB SCIENCE CO., LTD. for an M3 mutant peptide composition. The composition is directed to alleviating, inhibiting, preventing, or treating myopathy, obesity, or diabetes, and is classified under CPC codes A61K 38/4886, C12N 9/6489, A61P 3/04, A61P 3/10, and A61P 21/00.
Patent holders and parties licensing or developing peptide-based therapeutics for metabolic or muscular disorders should review this grant to assess freedom-to-operate for related compositions or methods. The grant confers enforceable IP rights in the United States but does not impose regulatory compliance obligations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition for treating or preventing myopathy, obesity or diabetes
Grant US12605431B2 Kind: B2 Apr 21, 2026
Assignee
NB SCIENCE CO., LTD.
Inventors
Bong Keun Choi, Sung Kwon Lee, Sang Hyup Lee
Abstract
The present invention relates to: an M3 mutant peptide; a composition for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes, comprising same as an active ingredient; a method for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes by using the M3 mutant peptide; and uses of the M3 mutant peptide for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes.
CPC Classifications
A61K 38/4886 C12N 9/6489 A61P 3/04 A61P 3/10 A61P 21/00
Filing Date
2021-12-14
Application No.
18267252
Claims
5
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.